Managing Partner at MedTech Impact Partners || Venture Partner at Wavemaker Three-Sixty Health
Key takeaway from MedTech MVP's "Breakthrough Device Panel Discussion": "While patient impact is advanced by improved times for novel devices (via the De Novo or PMA) there remains opportunity. The 510(k) is the most common application type and the "workhorse" for medtech innovation. Here we can stand to get more innovative solutions." #medtechmvp #breakthroughdevices #510kpathway #denovo #thoughtleadership #conferencerecap
Share your thoughts on what these solutions would need to include!
What are your thoughts on which approval process creates higher enterprise value upon exit? (and pre- or post- approval?)
Enjoyed the conversation 👊
I’m sorry I missed this panel! I’m sure it was exceptional Kwame Ulmer !
Keep up the good work, Kwame!
Managing Partner at MedTech Impact Partners || Venture Partner at Wavemaker Three-Sixty Health
6moOur research suggests De Novo devices create more enterprise value than 510(k) devices. We have written a memo on the pros and cons of De Novo devices.